As a bioinformatics company we perform our own in silico research on COVID-19. We applied Genome Enhancer tool to publicly available COVID-19 datasets to identify prospective drug targets and treatments for this infection. The results of our studies were shared by geneXplain’s CSO Dr. Alexander Kel during our recent masterclasses, the video records of which are available below.
This video is a record of geneXplain’s live masterclass ‘COVID-19 – online discovery of prospective drug targets and personalized treatments with Genome Enhancer’ which was held on April 29th, 2020.
In this video geneXplain’s CSO Dr. Alexander Kel is performing the analysis of personalized transcriptomics data coming from bronchoalveolar lavage of certain COVID-19 patients using the Genome Enhancer software.
This video is a record of geneXplain’s live masterclass ‘COVID-19 – online discovery of prospective drug targets and treatments with Genome Enhancer’ which was held on April 7th, 2020.
In this video geneXplain’s CSO Dr. Alexander Kel is performing the integrated analysis of transcriptomics and proteomics datasets of COVID-19 patient data in search for prospective drug targets and treatments using the Genome Enhancer software.
In another study we have applied TRANSFAC database to identify transcription factors governing the regulation of the LZTFL1 gene, identified in a recent publication as a candidate effector gene at a COVID-19 risk locus. You can watch our CEO Dr. Alexander Kel commenting on that study in the video below, or you are very much welcome to view a short article prepared by us in connection to this investigation